Poorly informed stakeholders

It is crucial to give clear and correct information to all stakeholders (policy makers, patients, doctors, regulators, healthcare payers, Contract Research Organisations (CRO), technology providers, executives of biomedical companies, etc.) on the opportunities and the risks associated with the use of In Silico Trials technologies. Each stakeholder will thus benefit of a rigorous risk-benefit evaluation framework to assess the adoption of In Silico Trials technologies.

Our goal:

Responsible Research & Innovation: policies-watch; risk-benefit and cost-benefit analyses for healthcare professionals; monitor perception of IST among senior management of medical industries; promote citizen trust in IST.